921 results on '"Pestronk, A"'
Search Results
2. FTC rule excludes franchise agreements
3. Understanding terms in MSAs
4. Old host refuses to transfer bookings
5. Figuring out the right earnout formula
6. Can contracts curb social media posts?
7. The do's and don'ts of selling travel insurance
8. 5 things to know when buying an agency
9. Getting help with debit memos
10. Contracts to consider in agency purchases
11. Six tips for getting the best GDS deal
12. How not to be the 'merchant of record'
13. Defining terms in DOT'S airline refunds rule
14. Who will inherit your business?
15. Noncompetes are about to become illegal
16. The DOT has deputized state AGs
17. Is the DOT's refund rule still 'anti-agent'?
18. Client's DUI could keep him out of Canada
19. How to get rid of an IC
20. Amex GBT-CWT linkup is full of upside
21. Affiliating to meet AA's NDC requirement
22. Little legal recourse against AA's moves
23. Class action against airlines won't fly
24. The growing trend of verticalization
25. The legality of IC exclusivity
26. Why GDS contracts are full of dangers
27. Green flags in host agency contracts
28. Red flags in host agency contracts
29. More questions about selling an agency
30. A travel person's guide to selling an agency
31. There's no testing option for vaccine mandate
32. Keeping contracts up with the times
33. Inside Illinois' consumer-protection law
34. The key to working with DMCs
35. Selling adventure? Have a disclaimer
36. What employees, ICs can bring to your agency
37. Is there a duty to warn about Israel travel?
38. Steps to follow for a valid trust account
39. You likely need to have a privacy policy
40. No need to disclose markups to clients
41. Your duty to a client has its limits
42. Answers for a new advisor
43. What's negotiable for ICs? It depends
44. The bright side of long-term GDS contracts
45. ASTA's consumer-driven case against AA
46. NDC is wanting, but there's no avoiding it
47. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
48. Whose booking is it anyway?
49. Five elements to required disclosures
50. The big pro to errors and omissions coverage
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.